Our Director of Research Dr Sheona Scales describes her four highlights from this year's Clinical Trials on Alzheimer's ...

Today, the first monoclonal antibodies, lecanemab and donanemab, are available, showing that their reduction effect on these ...

There is a lot of outrage that the new Alzheimer’s drug donanemab is being refused on the NHS. But there are good reasons for ...

Anti-amyloid antibodies lecanemab and donanemab are in clinical use now, but that does not mean research on them has stopped. At the Clinical Trials on Alzheimer’s Disease conference, held October ...

Alzheimer’s trials face the unique challenge of studying participants with cognitive decline, amid a move towards digital ...

Seeking ways to improve the safety of anti-amyloid antibodies, John Sims of Eli Lilly & Company presented a simple option to do so for donanemab at this year’s Clinical Trials on Alzheimer’s Disease ...

The drug Donanemab has been found to slow the progression of Alzheimer’s disease. Despite this is has been rejected for widespread use in the health service in England after the health spending ...

Peter Almond finished a trial for Donanemab in September having been on the drug for three years. Donanemab is one of the new “disease modifying” treatments for Alzheimer’s disease ...

The association said new treatments have become available that slow the progression of Alzheimer’s for those in the early ...

Donanemab was evaluated in a main study (Phase III Study TRAILBLAZER-ALZ 2) involving 1,736 patients with early Alzheimer’s disease who had mild cognitive impairment, mild dementia and evidence ...

Donanemab can slow the progression of Alzheimer’s disease. But what is the drug and how does it work? Here your questions on the latest development in Alzheimer’s research are answered.

Donanemab, also known as Kisunla, has recently been licensed as a treatment for early-stage Alzheimer’s disease in the UK. However, donanemab has not been recommended for use in the NHS. Here's what ...